| Business Summary | | Genelabs
Technologies,
Inc.
is
a
biopharmaceutical
company
focused
on
discovering
and
developing
pharmaceutical
products.
The
Company
has
a
near-term
drug
candidate,
Aslera,
for
which
the
United
States
Food
and
Drug
Administration
(FDA)
is
reviewing
its
marketing
application.
Aslera
is
a
potential
new
treatment
for
systemic
lupus
erythematosus
(lupus).
In
the
longer
term,
the
Company's
DNA-binding
drug
discovery
program
may
have
the
potential
to
create
a
new
class
of
pharmaceutical
products
that
directly
target
DNA.
In
2000,
Genelabs
submitted
a
New
Drug
Application
for
Aslera,
as
a
treatment
for
lupus,
to
the
FDA.
Lupus
is
a
life-long
autoimmune
disease
that
causes
the
immune
system
to
attack
the
body's
own
tissues
and
organs.
The
Company
expects
to
receive
a
decision
from
the
FDA
on
approval
status
by
mid-year
2001.
Genelabs
intends
to
fund
the
discovery
and
development
of
future
products
from
royalties
received
on
sales
of
Aslera,
if
approved
by
the
FDA. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Genelabs,
a
biopharmaceutical
company,
focuses
its
research
on
the
discovery
of
small
molecule
drugs
that
function
by
binding
to
DNA
to
regulate
gene
expression
or
inactive
pathogens.
For
the
six
months
ended
6/30/01,
revenues
fell
29%
to
$2.6
million.
Net
loss
rose
3%
to
$6.5
million.
Revenues
reflect
the
completion
of
the
U.S.
Defense
Advanced
Research
Projects
Agency
grant.
Higher
loss
reflects
preparation
costs
for
the
potential
commercial
introduction
of
Aslera. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Irene Chow, Ph.D., 62 Chairman,
CEO | $502K | James Smith, 42 Pres,
Director | 298K | Matthew Loar, 38 VP-
Fin. | 199K | Heather Keller, 35 VP,
Gen. Counsel, Sec. | 202K | Lynn Hughes, 45 VP
of HR and Corp. Services | -- | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|